Biomind Labs Inc.
Biomind Labs Inc. (BMNDF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bmndf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Biomind Labs Inc. (BMNDF) measures how much investors pay for each dollar of the company's trailing earnings. BMNDF's current PE ratio of N/A is calculated by dividing its stock price of $0.12 by its TTM earnings per share of -$0.01.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%47.3x
MedianQ3 · 75%2956.5x
Max
At N/A, BMNDF's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Biomind Labs Inc.You BMNDF | $9M | N/A | — | -$0.01 |
 Biocure Technology Inc. BICTF | $1M | N/A | — | -$0.01 |
 Biora Therapeutics, Inc. BIOR | $1M | N/A | — | -$78.69 |
 Chia Tai Enterprises International Limited CAIHF | $1M | 2.21x | -15.2% | $0.13 |
 Target Group Inc. CBDY | $1M | N/A | — | -$0.00 |
 Enzolytics Inc. ENZC | $4M | N/A | — | -$0.00 |
 Evofem Biosciences, Inc. EVFM | $1M | 3.00x | +15.2% | $0.00 |
Industry Average 2 peers with valid PE | — | 2.61x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.01 | — | |
2024-12-31 FY2024 | — | $-0.00 | — | |
2023-12-31 FY2023 | — | $-0.02 | — | |
2022-12-31 FY2022 | — | $-0.04 | — | |
2021-12-31 FY2021 | — | $-0.06 | — | |
2020-12-31 FY2020 | — | $-0.02 | — | |
2019-12-31 FY2019 | — | $-0.04 | — | |
2018-12-31 FY2018 | — | $-0.12 | — | |
2017-12-31 FY2017 | — | $-0.02 | — | |
2016-12-31 FY2016 | — | $-0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Biomind Labs Inc. (BMNDF) measures how much investors pay for each dollar of the company's trailing earnings. BMNDF's current PE ratio of N/A is calculated by dividing its stock price of $0.12 by its TTM earnings per share of -$0.01.
Frequently asked questions
BMNDF pe ratio · 6 questionsBMNDF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.12 and TTM EPS of -$0.01. Data sourced from Financial Modeling Prep via BMNDF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biomind Labs Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09